Pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, Gland Pharma has informed that it enclosed the schedule of Analyst/ Institutional Investor Meetings with the Company.
The above information is a part of company’s filings submitted to BSE.